{"id":61975,"date":"2026-04-16T02:18:41","date_gmt":"2026-04-16T02:18:41","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/61975\/"},"modified":"2026-04-16T02:18:41","modified_gmt":"2026-04-16T02:18:41","slug":"goodrx-rallies-as-wegovy-hd-rollout-targets-self-pay-market-goodrx-holdings-nasdaqgdrx-novo-nordisk","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/61975\/","title":{"rendered":"GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market – GoodRx Holdings (NASDAQ:GDRX), Novo Nordisk"},"content":{"rendered":"

\u2022 GoodRx Holdings shares are advancing steadily. What\u2019s driving GDRX shares up?<\/a><\/p>\n

This move comes amid a growing demand for GLP-1 treatments<\/a>, which reflects GoodRx\u2019s ongoing efforts to simplify access to medications.<\/p>\n

GoodRx is a platform for medication savings in the U.S., used by nearly 25 million consumers and over one million healthcare professionals annually.<\/p>\n

In March, the U.S. Food and Drug Administration (FDA) approved a higher-dose version of\u00a0\u00a0Wegovy, marking an expansion of its treatment portfolio for adults with obesity<\/a>.<\/p>\n

Tiered Pricing Structure Offers Flexibility<\/p>\n

Pricing scales with quantity, with a two-month supply available for $798 and a three-month supply available for $1,197, giving consumers flexibility and clear expectations around cost<\/a>.<\/p>\n

For patients, Wegovy HD offers an additional FDA-approved step-up option within the Wegovy portfolio, potentially helping eligible patients achieve greater weight-loss benefit without requiring them to switch to a different brand or care pathway.<\/p>\n

GoodRx announced that the new Wegovy HD injection is now available to eligible self-pay patients, with pricing options scaling for multiple-month supplies.<\/p>\n

Last week, GoodRx revealed that it is expanding access to Eli Lilly and Company’s (NYSE:<\/a>LLY<\/a>) new oral GLP-1 medication, Foundayo.<\/p>\n

GoodRx announced that eligible self-pay consumers can access Foundayo starting at $149 per month<\/a>.<\/p>\n

The company is also expanding access to Zepbound, available to eligible self-pay patients starting at $299 per month at more than 70,000 pharmacies nationwide.<\/p>\n

Technical Indicators Show Short-Term Strength<\/p>\n

GoodRx\u2019s relative strength index (RSI) is at 56.74, which indicates neutral momentum, suggesting the stock is not currently overbought or oversold.<\/p>\n

Additionally, the moving average convergence divergence (MACD) is above its signal line, indicating bullish momentum, which may attract buyers looking for upward movement.<\/p>\n

Key Resistance: $2.50 \u2014 A level where selling pressure may increase.<\/p>\n

Key Support: $2 \u2014 A level where buying interest may emerge.<\/p>\n

Analyst Consensus & Recent Actions: The stock carries a Hold rating with an average price target<\/a> of $3.73. Recent analyst moves include:<\/p>\n

Wells Fargo: Overweight (Lowers target to $3.50 on March 4)<\/p>\n

Citigroup: Buy (Lowers target to $3.50 on March 3)<\/p>\n

Goldman Sachs: Neutral (Lowers target to $2.50 on March 2)<\/p>\n

GDRX Stock Price Activity: GoodRx Holdings shares were up 2.69% at $2.29 at the time of publication on Wednesday, according to Benzinga Pro data<\/a>.<\/p>\n

Image via Shutterstock<\/p>\n","protected":false},"excerpt":{"rendered":"\u2022 GoodRx Holdings shares are advancing steadily. What\u2019s driving GDRX shares up? This move comes amid a growing…\n","protected":false},"author":2,"featured_media":61976,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2085,2094,2089,2087,2092,2088,2093,2084,272,352,34019,8257,2096,2099,2100],"class_list":{"0":"post-61975","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-category-biotech","9":"tag-category-general","10":"tag-category-health-care","11":"tag-category-large-cap","12":"tag-category-movers","13":"tag-category-news","14":"tag-category-trading-ideas","15":"tag-cms-wordpress","16":"tag-novo-nordisk","17":"tag-pageisbzpro-bz","18":"tag-symbol-gdrx","19":"tag-symbol-lly","20":"tag-symbol-nvo","21":"tag-tag-weight-loss","22":"tag-tag-why-its-moving"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116411990518426813","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/61975","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=61975"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/61975\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/61976"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=61975"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=61975"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=61975"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}